CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Update

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) was the recipient of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 4,800 shares, a drop of 25.0% from the February 13th total of 6,400 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 8,600 shares, the days-to-cover ratio is presently 0.6 days.

CollPlant Biotechnologies Trading Up 3.5 %

Shares of CollPlant Biotechnologies stock opened at $3.27 on Friday. CollPlant Biotechnologies has a 12 month low of $3.00 and a 12 month high of $6.75. The firm has a market capitalization of $37.46 million, a P/E ratio of -2.12 and a beta of 1.07. The business has a fifty day simple moving average of $3.68 and a two-hundred day simple moving average of $4.09.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Benjamin Edwards Inc. purchased a new position in shares of CollPlant Biotechnologies during the third quarter valued at approximately $112,000. AMH Equity Ltd raised its stake in CollPlant Biotechnologies by 17.4% during the fourth quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after buying an additional 17,295 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in CollPlant Biotechnologies by 110.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock worth $30,000 after acquiring an additional 4,405 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of CollPlant Biotechnologies during the fourth quarter valued at $38,000. 21.69% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CLGN. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of CollPlant Biotechnologies in a research note on Friday, November 29th. D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 target price on shares of CollPlant Biotechnologies in a research report on Wednesday, February 12th.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.